How much funding has Maxymune Therapeutics raised?

Maxymune Therapeutics has disclosed $2.7M raised across 1 round.

Where is Maxymune Therapeutics headquartered?

Maxymune Therapeutics is headquartered in Los Altos, US.

Maxymune Therapeutics

Los Altos, US · Founded 2023 · Delaware corporation

Find your way into Maxymune Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Maxymune Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Maxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.

Biotech Healthtech

Founders & leadership

Tatjana NarandaNamed on SEC filing

Gordon RingoldNamed on SEC filing

Board

Neil SolomonsBoard director

Reported raises · per SEC filings

Form D private placements

$2.7M disclosed across 1 round · 2025

▶$2.7MraisedJun 2026 · 15 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Tatjana NarandaExecutive Officer, Director
Neil SolomonsDirector
Gordon RingoldExecutive Officer, Director

Offering amount: $4.5M
Amount sold: $2.7M
Minimum investment: $10K
First sale: Feb 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 9

Primmune TherapeuticsPrimmune Therapeutics develops PRTX007, an orally administered, systemically active TLR7 agonist that activates interferon-associated innate immune pathways for use in cancer immunotherapy. The candidate is being developed for oncology applications, including combination with immune checkpoint inhibitors and neoadjuvant/adjuvant settings, and has been tested in two Phase 1 studies in healthy volunteers.

ThymmuneThymmune Therapeutics develops a machine learning-driven thymic cell engineering platform that mass-produces iPSC-derived thymic cells to restore immune function affected by aging and disease. The company is building a pipeline of off-the-shelf cell therapies for immunodeficiencies, transplant-related, and autoimmune disorders.

AdaptimmuneAdaptimmune Therapeutics is a biotechnology company, though the specific focus of their therapeutic work is not detailed on this investors and media page.

ImmunomeImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.

MindImmune TherapeuticsMindImmune develops therapeutics targeting the immune drivers of neurodegenerative diseases such as Alzheimer's, focusing on immune cells that respond to amyloid plaques before they enter the brain. Its lead candidate, MITI-101, is a monoclonal antibody that blocks a key receptor to prevent neuroinflammation, neurite damage, and vascular pathology, with human trials planned for early 2027.

NexImmuneNexImmune is a biotechnology company developing antigen-directed immunotherapies based on its proprietary AIM nanoparticle platform, which mimics dendritic cell signaling to activate antigen-specific T cell responses. Its programs target oncology, autoimmune disorders, and infectious disease using formats including adoptive cell therapy (AIM ACT) and direct injection (AIM INJ).

GeorgiamuneGeorgiamune is a biopharmaceutical company developing targeted immunomodulator drugs that activate or down-modulate immune signaling pathways to treat cancer and autoimmune diseases. It operates a target discovery platform that supports a pipeline of first-in-class assets.

EvommuneEvommune develops therapies targeting the underlying sources of chronic inflammatory diseases, aiming to provide underserved patient populations with more than symptomatic relief. The company runs discovery and development programs with a focus on immunology.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Maxymune Therapeutics.

Frequently asked questions

What does Maxymune Therapeutics do?: Maxymune is a pharmaceutical company developing treatments for immunological diseases, including a small-molecule LAT1 inhibitor program targeting overactive T-cells in autoimmune conditions and an improved formulation of mycophenolic acid intended to reduce gastrointestinal side effects. Its work spans drug discovery and formulation of immunosuppressive therapies for patients with immunological disorders.
How much funding has Maxymune Therapeutics raised?: Maxymune Therapeutics has disclosed $2.7M raised across 1 round.
Where is Maxymune Therapeutics headquartered?: Maxymune Therapeutics is headquartered in Los Altos, US.